Dr Edwin Lim proposed the first biomarker to discriminate MS clinical subtypes using tryptophan metabolomics. His work aims to deliver a reliable prognostic biomarker to track neurological and mental wellbeing.
Dr Lim’s international collaboration with Associate Professor Sophie Erhardt and Associate Professor Lena Brundin led to the discovery of a biomarker that can discriminate individuals with a likelihood to attempt suicide. This biomarker was shown to work regardless to the subjects predisposition to mental illness. Such prognostic biomarkers provide clinicians with better decision making when monitoring a patient’s disease progression. These biomarkers also help determine drug efficacy through reflecting the patient’s response to novel treatments.
Dr Lim has extended this approach towards profiling tryptophan metabolomics to several other neurological diseases including Alzheimer’s diseases, depression, Schizophrenia and more recently, autism. His research also looks at the influence of environmental factors such as sunlight exposure and pathogens that interact with tryptophan metabolism indirectly and directly.